Kura Oncology spins off diabetes assets into new company backed by Lilly
Kura Oncology is divesting its diabetes research into a separate entity, which has received $50 million in funding and support from Eli Lilly. The new company will focus on developing metabolic therapies. Kura will retain its focus on oncology, particularly its leukemia drug Komzifti.
Kura Oncology is restructuring its pipeline by separating its diabetes research into a newly formed independent company. This new venture has secured $50 million in initial funding and backing from Eli Lilly.
The newly established entity will concentrate its efforts on developing metabolic therapies. Meanwhile, Kura Oncology will narrow its corporate focus to oncology, specifically advancing its leukemia treatment, Komzifti.
This corporate split could influence the development of new treatments for metabolic conditions, as the dedicated funding from Eli Lilly may accelerate research in that area. Patients with diabetes or related disorders might eventually benefit from a more focused pipeline. Conversely, Kura's concentration on oncology could sharpen its efforts in cancer care, potentially leading to more targeted therapies for leukemia patients. The broader pharmaceutical landscape may see increased specialization as companies spin off non-core assets.